State Street Corp Glycomimetics Inc Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Glycomimetics Inc stock. As of the latest transaction made, State Street Corp holds 179,265 shares of GLYC stock, worth $44,816. This represents 0.0% of its overall portfolio holdings.

Number of Shares

179,265

Previous 179,265 -0.0%

Holding current value

$44,816

Previous $50,000 40.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.55 - $3.49 $19,125 - $26,175	-7,500 Reduced 4.02%	179,265 $537,000
Q1 2023 May 15, 2023	BUY	$1.25 - $4.05 $37,750 - $122,310	30,200 Added 19.29%	186,765 $235,000
Q4 2022 Feb 14, 2023	BUY	$0.57 - $3.03 $4,332 - $23,028	7,600 Added 5.1%	156,565 $474,000
Q1 2022 May 16, 2022	BUY	$1.0 - $1.58 $4,700 - $7,426	4,700 Added 3.26%	148,965 $170,000
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $1.1 Million - $1.62 Million	-509,897 Reduced 77.95%	144,265 $335,000
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $141,242 - $206,244	-48,873 Reduced 6.95%	654,162 $1.97 Million
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $83,188 - $131,122	30,925 Added 4.6%	703,035 $2.64 Million
Q3 2020 Nov 10, 2020	BUY	$3.07 - $5.0 $58,041 - $94,530	18,906 Added 2.89%	672,110 $2.06 Million
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $63,124 - $115,217	30,643 Added 4.92%	653,204 $2.46 Million
Q1 2020 May 11, 2020	BUY	$1.83 - $5.41 $1.14 Million - $3.37 Million	622,561 New	622,561 $1.42 Million

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.1M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Glycomimetics Inc Transaction History